Menu Back toSession-4C-IDMP

DIA Annual Canadian Meeting

Session 4C: Identification of Medicinal Products (IDMP)- Updates and Implementation Approaches

    Session Chair(s)
      Maggie  Graham

      Maggie Graham

      • Senior Policy Analyst, Natural and Non-Prescription Health Products Directorate
      • Health Canada, Canada
    The ISO IDMP standard, and the European implementation of it, present a number of challenges in terms of the data that must be collected, managed, and submitted to the agencies. Explore how companies can – and should already be starting to – approach IDMP implmentation. Speakers will address how to design new processes for handling IDMP requirements and how to react to evolving requirements.
      Donald  Palmer, MA

      Session Co-Chair

      Donald Palmer, MA

      • Associate Director, RIM-PM
      • Regeneron Pharmaceuticals, Inc, United States
      Joel  Finkle

      IDMP: Incrememental Data, More Processes

      Joel Finkle

      • Director, Regulatory Innovation & IDMP Strategy
      • ACUTA LLC, United States
      Vikesh  Srivastava

      IDMP Overview and a Regulators Perspective

      Vikesh Srivastava

      • Associate Director, Business Informatics Division, HPFB
      • Health Canada, Canada
      Brooke  Casselberry, MS, RAC

      Industry Perception and Action on IDMP Standards: US and EU

      Brooke Casselberry, MS, RAC

      • Owner
      • Cyan Life Sciences, United States

Contact us